Cosentyx® (secukinumab) achieved statistically significant and clinically meaningful sustained remission vs placebo at Week 521Trial showed reduction in annual cumulative steroid dose vs placebo ...
Novartis said that its immunology drug Cosentyx met the primary target and all secondary ones in a late-stage trial for the treatment of patients with inflammatory disease polymyalgia rheumatica.
I am a healthy 69-year-old female. I walk every day and belong to an exercise group that I attend twice a week. I’m writing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback